MINNEAPOLIS, April 8, 2020 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ: TECH) today announced that management will
host a conference call and webcast on Thursday, April 30, 2020, at 8:00 a.m. CDT to review third quarter 2020
financial results.
Access to the discussion may be obtained as follows:
Time:
|
8:00 a.m.
CDT
|
Date:
|
April 30,
2020
|
Dial-in:
|
1-877-407-9208 or
1-201-493-6784 (for international callers)
|
Conference
ID:
|
13701798
|
Webcast:
|
http://public.viavid.com/index.php?id=139066
|
A recorded rebroadcast will be available for interested parties
unable to participate in the live conference call by dialing
1-844-512-2921 or 1-412-317-6671 (for international callers) and
referencing Conference ID 13701798 or by going to:
http://audio.viavid.com/20200430-139066-bio-techne.mp3
The replay will be available from 11:00
a.m. CDT on Thursday, April 30, 2020 until 11:00 p.m. CDT on Saturday, May 30, 2020.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and
manufacturer of high-quality purified proteins and reagent
solutions - notably cytokines and growth factors, antibodies,
immunoassays, biologically active small molecule compounds, tissue
culture reagents and T-Cell activation technologies. Bio-Techne's
product portfolio also includes protein analysis solutions, sold
under the ProteinSimple brand name, offering researchers efficient
and streamlined options for automated western blot and multiplexed
ELISA workflow. These reagent and protein analysis solutions are
sold to biomedical researchers as well as clinical research
laboratories and constitute the Protein Sciences Segment.
Bio-Techne also develops and manufactures diagnostic products
including FDA-regulated controls, calibrators, blood gas and
clinical chemistry controls and custom assay development on
dedicated clinical instruments. Bio-Techne's genomic tools include
advanced tissue-based in-situ hybridization assays (ISH) for
research and clinical use, sold under the ACD brand as well as a
portfolio of clinical molecular diagnostic oncology assays,
including the ExoDx®Prostate(IntelliScore) test
(EPI) for prostate cancer diagnosis. These diagnostic and genomic
products comprise Bio-Techne's Diagnostics and Genomics Segment.
Bio-Techne products are integral components of scientific
investigations into biological processes and molecular diagnostics,
revealing the nature, diagnosis, etiology and progression of
specific diseases. They aid in drug discovery efforts and provide
the means for accurate clinical tests and diagnoses. With thousands
of products in its portfolio, Bio-Techne generated approximately
$714 million in net sales in fiscal
2019 and has over 2,200 employees worldwide.
Contact:
|
David Clair, Senior
Director, Investor Relations & Corporate Development
|
|
david.clair@bio-techne.com
|
|
612-656-4416
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-april-30-2020-to-announce-third-quarter-2020-financial-results-301037123.html
SOURCE Bio-Techne Corporation